A phase III trial of sunitinib has met its primary endpoint of disease-free survival for adjuvant treatment of high-risk renal cell carcinoma after nephrectomy, researchers report.

Source: Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer


David Cottle

UBB Owner & Administrator